(NASDAQ: CORT) Corcept Therapeutics's forecast annual revenue growth rate of 22.44% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 50.27%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.79%.
Corcept Therapeutics's revenue in 2025 is $628,555,000.On average, 4 Wall Street analysts forecast CORT's revenue for 2025 to be $81,190,253,661, with the lowest CORT revenue forecast at $78,809,762,549, and the highest CORT revenue forecast at $84,040,137,388. On average, 3 Wall Street analysts forecast CORT's revenue for 2026 to be $99,686,208,596, with the lowest CORT revenue forecast at $90,690,215,333, and the highest CORT revenue forecast at $112,499,160,100.
In 2027, CORT is forecast to generate $121,738,231,680 in revenue, with the lowest revenue forecast at $109,280,467,891 and the highest revenue forecast at $134,195,995,470.